Background Ongoing Helicobacter pylori (HP) infection triggers a chronic active gastritis. Eradicating HP reduces gastric inflammation, but does not eliminate it. We sought to characterize this persistent gastritis, and demonstrate the persistence of HP-specific Th17 responses in individuals previously infected with HP but who no longer had evidence of ongoing infection. Methodology/Principal Findings Study subjects were divided into 3 groups 55 individuals had active HP infection (group A), 41 were diagnosed with previous HP infection (group P), and 59 were na？ve to HP (group N). Blood and gastric tissue were obtained with written informed consent from all subjects, and immune responses were evaluated using flow cytometry, semi-quantitative real time PCR, immunofluorescent staining, ELISA, and multiplex cytometric bead array for cytokine quantification. Elevated IL-17A responses were observed in patients from group A compared to group N. Interestingly, IL-17A responses remained persistently elevated in the blood and gastric mucosa of individuals from group P, despite the absence of ongoing HP infection. Using purified CD4+ T cells as effectors and antibodies that blocked antigen presentation by MHC Class II, we showed that these persistent IL-17A responses were mediated primarily by HP-specific Th17 cells, rather than other immune cells that have also been described to secrete IL-17A. Gastric mucosal IL-1β levels were also persistently elevated in group P, and neutralisation of IL-1β reduced the HP-specific IL-17A response of purified CD4+ T cells to autologous HP-pulsed antigen presenting cells in vitro, suggesting a functional association between IL-1β and the persistent Th17 response in group P patients. Conclusions/Significance Despite lack of ongoing HP infection, HP-specific Th17 cells persist in the blood and gastric mucosa of individuals with past HP infection. We speculate that this persistent inflammation might contribute to gastric mucosal pathology, for example, persistent increased gastric cancer risk despite eradication of HP.
References
[1]
Atherton JC, Blaser MJ (2009) Coadaptation of Helicobacter pylori and humans: ancient history, modern implications. J Clin Invest 119: 2475–2487.
[2]
Aebischer T, Meyer TF, Andersen LP (2010) Inflammation, immunity, and vaccines for Helicobacter. Helicobacter 15: 21–28.
[3]
Wilson KT, Crabtree JE (2007) Immunology of Helicobacter pylori: insights into the failure of the immune response and perspectives on vaccine studies. Gastroenterology 133: 288–308.
[4]
Yamauchi K, Choi IJ, Lu H, Ogiwara H, Graham DY, et al. (2008) Regulation of IL-18 in Helicobacter pylori infection. J Immunol 180: 1207–1216.
[5]
D’Elios MM, Manghetti M, De Carli M, Costa F, Baldari CT, et al. (1997) T helper 1 effector cells specific for Helicobacter pylori in the gastric antrum of patients with peptic ulcer disease. J Immunol 158: 962–967.
[6]
Karttunen R, Karttunen T, Ekre HP, MacDonald TT (1995) Interferon gamma and interleukin 4 secreting cells in the gastric antrum in Helicobacter pylori positive and negative gastritis. Gut 36: 341–345.
[7]
Sommer F, Faller G, Konturek P, Kirchner T, Hahn EG, et al. (1998) Antrum- and corpus mucosa-infiltrating CD4(+) lymphocytes in Helicobacter pylori gastritis display a Th1 phenotype. Infect Immun 66: 5543–5546.
[8]
Caruso R, Fina D, Paoluzi OA, Del Vecchio Blanco G, Stolfi C, et al. (2008) IL-23-mediated regulation of IL-17 production in Helicobacter pylori-infected gastric mucosa. Eur J Immunol 38: 470–478.
[9]
Luzza F, Parrello T, Monteleone G, Sebkova L, Romano M, et al. (2000) Up-regulation of IL-17 is associated with bioactive IL-8 expression in Helicobacter pylori-infected human gastric mucosa. J Immunol 165: 5332–5337.
[10]
Mizuno T, Ando T, Nobata K, Tsuzuki T, Maeda O, et al. (2005) Interleukin-17 levels in Helicobacter pylori-infected gastric mucosa and pathologic sequelae of colonization. World J Gastroenterol 11: 6305–6311.
[11]
Cua DJ, Tato CM (2010) Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol 10: 479–489.
[12]
Korn T, Bettelli E, Oukka M, Kuchroo VK (2009) IL-17 and Th17 Cells. Annu Rev Immunol 27: 485–517.
[13]
Cooper AM (2009) IL-17 and anti-bacterial immunity: protection versus tissue damage. Eur J Immunol 39: 649–652.
[14]
Onishi RM, Gaffen SL (2010) Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology 129: 311–321.
[15]
Parks WC, Wilson CL, Lopez-Boado YS (2004) Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 4: 617–629.
[16]
Wu S, Rhee K-J, Albesiano E, Rabizadeh S, Wu X, et al. (2009) A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nature Medicine 15: 1016–1022.
[17]
Zhang JP, Yan J, Xu J, Pang XH, Chen MS, et al. (2009) Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol 50: 980–989.
[18]
Zhu X, Mulcahy LA, Mohammed RA, Lee AH, Franks HA, et al. (2008) IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines. Breast Cancer Res 10: R95.
[19]
Iida T, Iwahashi M, Katsuda M, Ishida K, Nakamori M, et al. (2011) Tumor-infiltrating CD4+ Th17 cells produce IL-17 in tumor microenvironment and promote tumor progression in human gastric cancer. Oncol Rep 25: 1271–1277.
[20]
Maruyama T, Kono K, Mizukami Y, Kawaguchi Y, Mimura K, et al. (2010) Distribution of Th17 cells and FoxP3(+) regulatory T cells in tumor-infiltrating lymphocytes, tumor-draining lymph nodes and peripheral blood lymphocytes in patients with gastric cancer. Cancer Sci 101: 1947–1954.
[21]
National Institutes of Health Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease (1994) NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. JAMA 272: 65–69.
[22]
Mera R, Fontham ET, Bravo LE, Bravo JC, Piazuelo MB, et al. (2005) Long term follow up of patients treated for Helicobacter pylori infection. Gut 54: 1536–1540.
[23]
Hung LC, Ching JY, Sung JJ, To KF, Hui AJ, et al. (2005) Long-term outcome of Helicobacter pylori-negative idiopathic bleeding ulcers: a prospective cohort study. Gastroenterology 128: 1845–1850.
[24]
Wolk K, Witte E, Witte K, Warszawska K, Sabat R (2010) Biology of interleukin-22. Semin Immunopathol 32: 17–31.
[25]
Sonnenberg GF, Nair MG, Kirn TJ, Zaph C, Fouser LA, et al. (2010) Pathological versus protective functions of IL-22 in airway inflammation are regulated by IL-17A. J Exp Med 207: 1293–1305.
[26]
Xu S, Cao X (2010) Interleukin-17 and its expanding biological functions. Cell Mol Immunol 7: 164–174.
[27]
Acosta-Rodriguez EV, Rivino L, Geginat J, Jarrossay D, Gattorno M, et al. (2007) Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol 8: 639–646.
[28]
Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, et al. (2007) Phenotypic and functional features of human Th17 cells. J Exp Med 204: 1849–1861.
[29]
Wu YY, Tsai HF, Lin WC, Hsu PI, Shun CT, et al. (2007) Upregulation of CCL20 and recruitment of CCR6+ gastric infiltrating lymphocytes in Helicobacter pylori gastritis. Infect Immun 75: 4357–4363.
[30]
Yoshida A, Isomoto H, Hisatsune J, Nakayama M, Nakashima Y, et al. (2009) Enhanced expression of CCL20 in human Helicobacter pylori-associated gastritis. Clin Immunol 130: 290–297.
[31]
Ghannam S, Dejou C, Pedretti N, Giot JP, Dorgham K, et al. (2011) CCL20 and beta-defensin-2 induce arrest of human Th17 cells on inflamed endothelium in vitro under flow conditions. J Immunol 186: 1411–1420.
[32]
Yang D, Chertov O, Bykovskaia SN, Chen Q, Buffo MJ, et al. (1999) Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science 286: 525–528.
[33]
Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F (2007) Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 8: 942–949.
[34]
Ben-Sasson SZ, Hu-Li J, Quiel J, Cauchetaux S, Ratner M, et al. (2009) IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation. Proc Natl Acad Sci U S A 106: 7119–7124.
[35]
Rao DA, Tracey KJ, Pober JS (2007) IL-1alpha and IL-1beta are endogenous mediators linking cell injury to the adaptive alloimmune response. J Immunol 179: 6536–6546.
[36]
Romero-Gallo J, Harris EJ, Krishna U, Washington MK, Perez-Perez GI, et al. (2008) Effect of Helicobacter pylori eradication on gastric carcinogenesis. Lab Invest 88: 328–336.
[37]
El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, et al. (2000) Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 404: 398–402.
[38]
Persson C, Canedo P, Machado JC, El-Omar EM, Forman D (2011) Polymorphisms in inflammatory response genes and their association with gastric cancer: A HuGE systematic review and meta-analyses. Am J Epidemiol 173: 259–270.
[39]
Leung WK, Lin SR, Ching JY, To KF, Ng EK, et al. (2004) Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut 53: 1244–1249.
[40]
Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, et al. (2004) Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 291: 187–194.
[41]
Shibata T, Tahara T, Hirata I, Arisawa T (2009) Genetic polymorphism of interleukin-17A and ？17F genes in gastric carcinogenesis. Hum Immunol 70: 547–551.
[42]
Wu X, Zeng Z, Chen B, Yu J, Xue L, et al. (2010) Association between polymorphisms in interleukin-17A and interleukin-17F genes and risks of gastric cancer. Int J Cancer 127: 86–92.
[43]
Zhang B, Rong G, Wei H, Zhang M, Bi J, et al. (2008) The prevalence of Th17 cells in patients with gastric cancer. Biochem Biophys Res Commun 374: 533–537.
[44]
Hoffmann W (2005) Trefoil factors TFF (trefoil factor family) peptide-triggered signals promoting mucosal restitution. Cell Mol Life Sci 62: 2932–2938.
[45]
Lochter A, Galosy S, Muschler J, Freedman N, Werb Z, et al. (1997) Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J Cell Biol 139: 1861–1872.
[46]
Dhar DK, Wang TC, Tabara H, Tonomoto Y, Maruyama R, et al. (2005) Expression of trefoil factor family members correlates with patient prognosis and neoangiogenesis. Clin Cancer Res 11: 6472–6478.
[47]
Inoue T, Yashiro M, Nishimura S, Maeda K, Sawada T, et al. (1999) Matrix metalloproteinase-1 expression is a prognostic factor for patients with advanced gastric cancer. Int J Mol Med 4: 73–77.
